Skip to Main Content

Paper Details

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
Br J Cancer
15
2019
BRCA1, BRCA1/2, BRCA1/2 mutation, BRCA2, BRCA2 mutation, CIMBA, height-associated variants, ovarian cancer, women
Author NameAffiliation
Irene L AndrulisFred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital
Irene L AndrulisUniversity of Toronto
Irene L AndrulisFred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital
Irene L AndrulisUniversity of Toronto
Javier Ben??tezSpanish National Cancer Research Centre (CNIO)
Javier Ben??tez
Ian G CampbellPeter MacCallum Cancer Center
Ian G CampbellThe University of Melbourne
Fergus J CouchMayo Clinic
Fergus J CouchMayo Clinic
Susan M DomchekAbramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Douglas F EastonUniversity of Cambridge
Douglas F EastonUniversity of Cambridge
Rosalind A EelesThe Institute of Cancer Research and Royal Marsden NHS Foundation Trust
Judy E GarberCancer Risk and Prevention Clinic, Dana-Farber Cancer Institute
Peter J HulickCenter for Medical Genetics, NorthShore University HealthSystem
Peter J HulickThe University of Chicago Pritzker School of Medicine
Peter J HulickCenter for Medical Genetics, NorthShore University HealthSystem
Peter J HulickThe University of Chicago Pritzker School of Medicine
Claudine IsaacsLombardi Comprehensive Cancer Center, Georgetown University
Louise IzattClinical Genetics, Guy's and St Thomas' NHS Foundation Trust
Esther M Johnand Stanford Cancer Institute, Stanford University School of Medicine
Beth Y KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Jenny LesterWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Jan LubinskiPomeranian Medical University
Jan LubinskiPomeranian Medical University
Katherine L NathansonAbramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Paolo RadiceFondazione IRCCS Istituto Nazionale dei Tumori (INT)
Susan J RamusUniversity of NSW Sydney
Susan J RamusThe Kinghorn Cancer Centre, Garvan Institute of Medical Research
Susan J RamusUniversity of NSW Sydney
Susan J RamusThe Kinghorn Cancer Centre, Garvan Institute of Medical Research
Gustavo C RodriguezNorthShore University HealthSystem, University of Chicago
Doris SteinemannInstitute of Cell and Molecular Pathology, Hannover Medical School
Mary Beth TerryMailman School of Public Health, Columbia University
Christi J van AsperenLeiden University Medical Center
David E GoldgarHuntsman Cancer Institute, University of Utah School of Medicine
David E GoldgarHuntsman Cancer Institute, University of Utah School of Medicine
Georgia Chenevix-TrenchQIMR Berghofer Medical Research Institute
Georgia Chenevix-TrenchQIMR Berghofer Medical Research Institute
Timothy R RebbeckHarvard T.H. Chan School of Public Health
Timothy R RebbeckDana-Farber Cancer Institute
  • 1 - 42

Datasets